SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Growblox Sciences, Inc. – ‘10KSB’ for 3/31/04 – EX-14.1

On:  Tuesday, 6/22/04, at 4:25pm ET   ·   For:  3/31/04   ·   Accession #:  1193125-4-106541   ·   File #:  333-82580

Previous ‘10KSB’:  ‘10KSB’ on 7/24/03 for 3/31/03   ·   Next:  ‘10KSB’ on 7/13/05 for 3/31/05   ·   Latest:  ‘10KSB’ on 7/16/07 for 3/31/07   ·   8 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/22/04  Growblox Sciences, Inc.           10KSB       3/31/04    6:340K                                   RR Donnelley/FA

Annual Report — Small Business   —   Form 10-KSB
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10KSB       Fiscal Year Ended March 31, 2004                    HTML    268K 
 2: EX-14.1     Code of Ethics                                      HTML     10K 
 3: EX-31.1     Certification of Chief Executive Officer            HTML     12K 
 4: EX-31.2     Certification of Chief Financial Officer            HTML     12K 
 5: EX-32.1     Certification of Chief Executive Officer and Chief  HTML      7K 
                          Financial Officers                                     
 6: EX-99.1     Board of Directors Pre-Approval Policy              HTML     31K 


EX-14.1   —   Code of Ethics


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Code of Ethics  

Exhibit 14.1

 

FLAGSTICK VENTURES, INC.

 

(the “Company”)

 

CODE OF ETHICS FOR THE CEO AND SENIOR FINANCIAL OFFICERS

 

The Chief Executive Officer and all senior financial officers, including the Chief Financial Officer and principal accounting officer, are bound by the provisions set forth herein:

 

  1. The Chief Executive Officer and all senior financial officers are responsible for full, fair, accurate, timely, and understandable disclosure in the periodic reports required to be filed by the Company with the SEC. Accordingly, it is the responsibility of the Chief Executive Officer and each senior financial officer promptly to bring to the attention of the disclosure committee, if applicable, and the Board of Directors any material information of which he or she may become aware that affects the disclosures made by the Company in its public filings or otherwise assist the disclosure committee, if any, and the Board of Directors in fulfilling their responsibilities.

 

  2. The Chief Executive Officer and each senior financial officer shall promptly bring to the attention of the disclosure committee, if applicable, and the Board of Directors any information he or she may have concerning (a) significant deficiencies in the design or operation of internal controls that could adversely affect the Company’s ability to record, process, summarize, and report financial data or (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s financial reporting, disclosures or internal controls.

 

  3. The Chief Executive Officer and each senior financial officer shall promptly bring to the attention of the Board of Directors any information he or she may have concerning any violation of this Code, including any actual or apparent conflicts of interest between personal and professional relationships, involving any management or other employees who have a significant role in the Company’s financial reporting, disclosures or internal controls.

 

  4. The Chief Executive Officer and each senior financial officer shall promptly bring to the attention of the disclosure committee, if applicable, and the Board of Directors any information he or she may have concerning evidence of a material violation of the securities or other laws, rules or regulations applicable to the Company and the operation of its business, by the Company or any agent thereof, or of violation of this Code.

 

  5. The Board of Directors shall determine, or designate appropriate persons to determine, appropriate actions to be taken in the event of violations of this Code by the Chief Executive Officer and the Company’s senior financial officers. Such actions shall be reasonably designed to deter wrongdoing and to promote accountability for adherence to this Code, and may include written notices to the individual involved that the Board of Directors has determined that there has been a violation, censure by the Board of Directors, demotion or re-assignment of the individual involved, suspension with or without pay or benefits (as determined by the Board of Directors), and termination of the individual’s employment. In determining the appropriate action in a particular case, the Board of Directors or such designee shall take into account all relevant information, including the nature and severity of the violation, whether the violation was a single occurrence or repeated occurrences, whether the violation appears to have been intentional or inadvertent, whether the individual in question had been advised prior to the violation as to the proper course of action, and whether or not the individual in question had committed other violations in the past.

8 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/10/23  GB Sciences Inc.                  424B3                  1:2.5M                                   RDG Filings/FA
 7/14/23  GB Sciences Inc.                  10-K        3/31/23   65:8.5M                                   RDG Filings/FA
11/10/22  GB Sciences Inc.                  424B3                  1:2.9M                                   RDG Filings/FA
 6/30/22  GB Sciences Inc.                  10-K        3/31/22   72:10M                                    RDG Filings/FA
 9/21/21  GB Sciences Inc.                  424B3                  1:3.5M                                   RDG Filings/FA
 7/06/21  GB Sciences Inc.                  10-K        3/31/21   92:11M                                    RDG Filings/FA
 1/28/21  GB Sciences Inc.                  424B3                  1:5.2M                                   RDG Filings/FA
 8/28/20  GB Sciences Inc.                  10-K        3/31/20   96:12M                                    RDG Filings/FA
Top
Filing Submission 0001193125-04-106541   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 6, 7:55:07.2am ET